Crispr Therapeutics shares tumble after significant earnings miss
Geoffrey Beran Rose, Chief Commercial Officer of Pulmonx Corp (NASDAQ:LUNG), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transaction comes as the stock has experienced an 11.2% decline over the past week, despite showing strong momentum with a 20.6% gain year-to-date. According to InvestingPro analysis, the stock is currently trading near its Fair Value. On March 3, 2025, Rose sold a total of 5,779 shares across several transactions, amounting to $41,191.
The transactions included four separate sales. The first sale involved 520 shares at a price of $7.12 each, totaling $3,702. The second sale included 915 shares at the same price, totaling $6,514. The third transaction was the largest, with 2,327 shares sold at $7.14 each, bringing in $16,614. Finally, 2,017 shares were sold at $7.12 each, totaling $14,361.
These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted in previous years. Following these transactions, Rose retains ownership of 285,278 shares in the company.
Additionally, Rose was granted 108,000 RSUs, which will vest in equal quarterly installments over four years starting from March 3, 2025. These transactions reflect Rose’s ongoing management of his equity stake in the company.
In other recent news, Pulmonx Corp reported a strong fourth quarter for 2024, with revenue reaching $23.8 million, a 23% increase year-over-year. This figure exceeded the consensus estimate of $22.3 million, driven by a 16% rise in U.S. sales and a remarkable 42% growth internationally. Pulmonx’s earnings per share (EPS) also surpassed expectations, coming in at -$0.33 compared to the forecasted -$0.4475. Despite the positive revenue growth, the company’s gross margin slightly decreased to 74%, aligning with Street expectations. Citi analysts responded to these developments by raising Pulmonx’s stock price target to $8.00, maintaining a Neutral rating. Looking forward, Pulmonx projects 2025 revenue between $96 million and $98 million, indicating a growth of 16%-18% in constant currency terms. The company continues to focus on expanding its market presence and launching new products, which could further bolster its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.